home · filing · 0001140361-24-032511
8-K filed July 5, 2024, 7:59 PM ET
ticker GYRE
CIK 0001124105
regulatory
confidence high
sentiment negative
materiality 0.70
Director resigns; Nasdaq confirms Gyre out of compliance on audit committee composition
GYRE THERAPEUTICS, INC.
Nassim Usman resigned from Board and Audit Committee, effective June 30, 2024, not due to any disagreements.
On July 2, Nasdaq notified Gyre of non-compliance with Listing Rule 5605 (audit committee independence requirements).
Cure period runs until earlier of next annual meeting or June 30, 2025; company is recruiting a new independent director.
Company intends to reestablish compliance within cure period and avoid delisting.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-06-30
Filed July 5, 2024, 7:59 PM ET
On June 28, 2024, Nassim Usman, Ph.D. informed the Company that he intended to resign from the Board, effective as of June 30, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Nassim Usman resigned as Director at GYRE THERAPEUTICS, INC..
Action resigned
Role Director
Exact text from the filing
On June 28, 2024, Nassim Usman, Ph.D. informed the Company that he intended to resign from the Board, effective as of June 30, 2024.
View on SEC.gov
Source: SEC EDGAR
accession 0001140361-24-032511
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.